Novo Nordisk’s Wegovy Gets EU Thumbs Up But Launch Will Wait

Based On Positive Phase III Data

 
• By Ayisha Sharma
  
Non-Diabetic Obese Or Overweight Patients In The STEP Trials Saw 17-18% Weight Loss • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip